Related Experiment Video
Updated: Mar 28, 2026
10:46
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
11.2K
Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants
Ralf Gold1, Krzysztof W Selmaj2,3, Regina Berkovich4
1Neurologische Universitätsklinik, St. Josef Hospital, Bochum, Germany.
Annals of Clinical and Translational Neurology
|March 27, 2026
Summary
Most multiple sclerosis patients discontinuing ozanimod did not experience disease activity rebound. Post-treatment relapses were infrequent and generally mild, with most patients recovering fully.
Area of Science:
- Neurology
- Immunology
- Pharmacology
Background:
- Discontinuing disease-modifying therapies (DMTs) for multiple sclerosis (MS) can lead to disease activity return.
- Some MS DMTs are linked to a higher-than-expected disease activity, known as rebound, post-discontinuation.
- Ozanimod is an MS DMT, and its discontinuation effects require assessment.
Purpose of the Study:
- To explore disease activity and the risk of rebound after discontinuing ozanimod.
- To characterize post-treatment relapses in participants who stopped ozanimod therapy.
Main Methods:
- Analysis of data from the DAYBREAK open-label extension trial (NCT02576717) involving participants with relapsing MS.
- Participants received ozanimod 0.92 mg/d and had extended safety follow-up periods (up to 90 days).
- Confirmed post-treatment relapses were identified and characterized, including severity and recovery.
Main Results:
- Of 1679 participants with follow-up, 3.3% (55 participants) experienced a post-treatment relapse.
- Most relapses (54/55) occurred when participants were not taking another MS DMT.
- Relapses typically involved mild to moderate increases in Expanded Disability Status Scale (EDSS) scores, with most participants recovering fully or partially.
Conclusions:
- A low incidence of relapse was observed within 90 days of ozanimod discontinuation.
- No clear cases suggestive of a rebound effect were identified following ozanimod cessation.
- Ozanimod discontinuation appears to have a manageable safety profile regarding disease activity return.
Related Concept Videos
01:24Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
01:24Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
334
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
334
01:29Therapeutic Drug Monitoring: Affecting Factors
328
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
328
01:15REM Sleep Behavior Disorder
2.4K
REM Sleep Behavior Disorder (RBD) is a sleep disorder characterized by the absence of muscle paralysis that normally occurs during the REM phase of sleep. This absence allows individuals to physically act out their dreams, which are often vivid and disturbing. Common behaviors exhibited during episodes include kicking, punching, and yelling. These actions can be dangerous, potentially leading to injuries for the person with RBD or their bed partner.
RBD is significantly associated with...
RBD is significantly associated with...
2.4K
01:21Drug Accumulation During Multiple Dosing: Repetitive IV Injections
384
Calculating drug dosage and accumulation in multiple-dose regimens is crucial for achieving therapeutic efficacy while avoiding toxicity. This involves determining the plasma drug concentrations over time to optimize dosing schedules. The principle of superposition is fundamental in this process, allowing for the prediction of drug concentration in plasma following multiple doses based on single-dose data.The principle of superposition asserts that the plasma concentration-time curves from...
384